Skip to Content
scroll

Immutep Ltd (IMM)

ASX.IMM $0.34

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

IMM $0.34

20 MINUTE DELAYED

TODAY

-4.23 %

1 YEAR RETURN

0.00%

VOLUME

3,957,655

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.23

0.48

ANALYSIS

i

PERFORMANCE

image description

i

SHARE PRICE ACTIVITY
Last (Price)

0.34

Change

-0.02 (-4.23)

Bid / Ask

0.34 - 0.35

Volume

3,957,655

Turnover

1,374,721

Open

0.35

Day Range

0.34 - 0.36

VWAP

0.35

Prev Close

0.36

Last Trade

17/09 4:10pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

0

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00

PREVIOUS SECTION

ANNOUNCEMENTS

NEXT SECTION

RATIOS

image description

Business Summary

Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. Its other two product candidates include leramilimab (IMP701), an immunotherapy for solid tumors, blood cancer and breast cancer, and GSK‘781 (IMP731) an immunotherapy for autoimmune diseases. The Company’s subsidiaries include Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

image description

Relevant suggested news and content from the site

image description
Movers & Losers
image description
Market Matters Video Update – Portfolio Performance & Positioning for August 2024 with Shawn & James
image description
Tuesday 17th September – ASX up 22pts, PTM/RPL & NHC
image description
Overview
image description
The Call with Market Matters Research Lead Shawn Hickman
image description
Tuesday 17th September – Dow up +228pts, SPI up +53pts
image description
New Hope Corp Ltd (NHC)
image description
Markets @ Midday – Monday 16th September – ASX +33pts, MIN & AIA
image description
ASX200 Index
image description
Monday 16th September – Dow +297pts, SPI up 16pts
image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top